Pharmacoepidemiology of patients hospitalized for somatoform disorders in psychiatric hospitals and departments

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 7, 2010, Pages 687-693

  Mundt, Adrian ^a   Ströhle, Andreas ^a   Heimann, Hannah ^a   Heinz, Andreas ^a   Grohmann, Renate ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Pharmacoepidemiology; Psychiatric in patients; Somatoform disorders

Indexed keywords

AMITRIPTYLINE; ANTIASTHMATIC AGENT; ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; ANTITUSSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CITALOPRAM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXEPIN; DULOXETINE; ESCITALOPRAM; HYPNOTIC AGENT; MELPERONE; MIRTAZAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; PAROXETINE; PERAZINE; PIPAMPERONE; PROMETHAZINE; PROTON PUMP INHIBITOR; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SERTRALINE; TRANQUILIZER; TRIMIPRAMINE; UNINDEXED DRUG; VENLAFAXINE;

ARTICLE; HUMAN; MAJOR CLINICAL STUDY; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; SOMATOFORM DISORDER; ADULT; CLINICAL PRACTICE; CROSS-SECTIONAL STUDY; DRUG COMBINATION; EUROPE; FEMALE; HOSPITALIZATION; MALE; MENTAL HOSPITAL; MIDDLE AGED; POLYPHARMACY; SOMATOFORM DISORDERS; STATISTICS AND NUMERICAL DATA;

ADULT; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; HOSPITALIZATION; HOSPITALS, PSYCHIATRIC; HUMANS; MALE; MIDDLE AGED; PHARMACOEPIDEMIOLOGY; PHYSICIAN'S PRACTICE PATTERNS; POLYPHARMACY; PSYCHOTROPIC DRUGS; SOMATOFORM DISORDERS;

EID: 77955614692     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1976     Document Type: Article

References (24)

1. Mayou R, Kirmayer LJ, Simon G, Kroenke K, Sharpe M. Somatoform disorders: time for a new approach in DSM-V. Am J Psychiatr 2005; 162: 847-855. (Pubitemid 40676195)
2. Kirmayer LJ, Groleau D, Looper KJ, Dao MD. Explaining medically unexplained symptoms. Can J Psychiatr 2004; 49: 663-672.
3. Khan AA, Khan A, Harezlak J, Tu W, Kroenke K. Somatic symptoms in primary care: etiology and outcome. Psychosomatics 2003; 44: 471-478. (Pubitemid 37352224)
4. Fink P, Hansen MS, Oxhoj ML. The prevalence of somatoform disorders among internal medical inpatients. J Psychosom Res 2004; 56: 413-418. (Pubitemid 38490729)
5. Hansen MS, Fink P, Sondergaard L, Frydenberg M. Mental illness and health care use: a study among new neurological patients. Gen Hosp Psychiatr 2005; 27: 119-124. (Pubitemid 40348776)
6. Reid S, Wessely S, Crayford T, Hotopf M. Frequent attenders with medically unexplained symptoms: service use and costs in secondary care. Br J Psychiatr 2002; 180: 248-253.
7. Hiller W, Fichter MM. High utilizers of medical care: a crucial subgroup among somatizing patients. J Psychosom Res 2004; 56: 437-443. (Pubitemid 38490733)
8. Morley S, Eccleston C, Williams A. Systematic review and meta-analysis of randomized controlled trials of cognitive behaviour therapy and behaviour therapy for chronic pain in adults, excluding headache. Pain 1999; 80: 1-13. (Pubitemid 29151684)
9. Henningsen P, Zipfel S, Herzog W. Management of functional somatic syndromes. Lancet 2007; 369: 946-955.
10. Volz HP, Stieglitz RD, Menges K, Moller HJ. Somatoform disorders - diagnostic concept, controlled clinical trials, and methodological issues. Pharmacopsychiatry 1994; 27: 231-237. (Pubitemid 24337138)
11. Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS. Do antidepressants have an analgesic effect in psychogenic pain and somatoform pain disorder? A meta-analysis. Psychosom. Med 1998; 60: 503-509.
12. Kroenke K. Efficacy of treatment for somatoform disorders: a review of randomized controlled trials. Psychosom Med 2007; 69: 881-888. (Pubitemid 350158831)
13. Harnack D, Scheel M, Mundt A, Kupsch A, Heinz A, Ströhle A. Pregabalin in patients with antidepressant treatment-resistant somatoform disorders: a case series. J Clin Psychopharmacol 2007; 27: 537-539. (Pubitemid 47415069)
14. Fallon BA. Pharmacotherapy of somatoform disorders. J Psychosom Res 2004; 56: 455-460.
15. Grohmann R, Engel RR, Ruther E, Hippius H. The AMSP drug safety program: methods and global results. Pharmacopsychiatry 2004; 37 Suppl 1: S4-11.
16. Grohmann R, Engel RR, Geissler KH, Ruther E. Psychotropic drug use in psychiatric inpatients: recent trends and changes over time-data from the AMSP study. Pharmacopsychiatry 2004; 37 (Suppl 1): S27-S38 (Pubitemid 38658328)
17. Heinze M, Andreae D, Grohmann R. Pharmacotherapy of personality disorders in German speaking countries: state and changes in the last decade. Pharmacopsychiatry 2005; 38: 201-205.
18. Wolfsperger M, Greil W, Rossler W, Grohmann R. Pharmacological treatment of acute mania in psychiatric in-patients between 1994 and 2004. J Affect Disord 2007; 99: 9-17.
19. Fink P, Hansen MS, Sondergaard L, Frydenberg M. Mental illness in new neurological patients. J Neurol Neurosurg Psychiatr 2003; 74: 817-819.
20. Raguram R, Weiss MG, Channabasavanna SM, Devins GM. Stigma, depression, and somatization in South India. Am J Psychiatr 1996; 153: 1043-1049.
21. Lieb R, Meinlschmidt G, Araya R. Epidemiology of the association between somatoform disorders and anxiety and depressive disorders: an update. Psychosom Med 2007; 69: 860-863.
22. Hasin D, Katz H. Somatoform andx substance use disorders. Psychosom Med 2007; 69: 870-875.
23. O'Malley PG, Jackson JL, Santoro J, Tomkins G, Balden E, Kroenke K. Antidepressant therapy for unexplained symptoms and symptom syndromes. J Fam Pract 1999; 48: 980-990.
24. Callahan AM, Fava M, Rosenbaum JF. Drug interactions in psychopharmacology. Psychiatr Clin North Am 1993; 16: 647-671.